Form 4: United Therapeutics CEO Rothblatt Executes Stock Option Exercises and Sales Under 10b5-1 Plan
SEC Form 4
Martine Rothblatt, Chairperson and CEO of United Therapeutics, executed stock option exercises and sales of common stock under a pre-arranged 10b5-1 trading plan on June 17 and 18, 2024.
Summary
- Martine Rothblatt, Chairperson and CEO of United Therapeutics, reported transactions involving the exercise of stock options and the sale of common stock on June 17 and 18, 2024.
- These transactions were executed under a pre-arranged 10b5-1 trading plan established on August 4, 2023.
- On both June 17 and June 18, 3,600 stock options were exercised at a price of $129.49 per share.
- The exercised shares were then sold in multiple transactions at varying prices, ranging from approximately $286 to $306 per share.
- The trading plan is set to continue until the earlier of the exhaustion of 723,869 stock options expiring on December 31, 2024, or August 31, 2024.
- Following these transactions, Rothblatt directly owns 130 shares of common stock and indirectly owns a significant number of shares through various trusts.
- Rothblatt directly owns 165,869 stock options.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating routine transactions under a pre-arranged trading plan. It doesn't inherently convey positive or negative sentiment.
Future Outlook
The 10b5-1 trading plan will continue until the earlier of August 31, 2024, or the exhaustion of 723,869 stock options expiring on December 31, 2024.
Industry Context
This filing is a routine disclosure of insider transactions, which are common among publicly traded companies. The use of a 10b5-1 trading plan allows insiders to sell shares over a predetermined period, mitigating concerns about trading on non-public information.
Comparison to Industry Standards
- 10b5-1 trading plans are a common practice among executives at publicly traded companies, including those in the biotechnology and pharmaceutical sectors like United Therapeutics.
- Companies such as Amgen, Gilead Sciences, and Biogen also see similar filings from their executives related to stock option exercises and sales under pre-arranged trading plans.
- The frequency and volume of these transactions can vary based on individual financial planning and company stock performance.
Key Dates
| Date | Description |
|---|---|
| 12/31/2014 | Date exercisable for stock options |
| 08/04/2023 | Date the 10b5-1 trading plan was entered into by the reporting person |
| 06/17/2024 | Date of earliest transaction (exercise and sale of stock options) |
| 06/18/2024 | Date of transaction (exercise and sale of stock options) |
| 06/20/2024 | Date of filing |
| 08/31/2024 | End date of the 10b5-1 trading plan (or earlier if options are exhausted) |
| 12/31/2024 | Expiration date of the tranche of 723,869 stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.